Multinodular goiters with hypothyroidism

Reading File

Researching multinodular goiter (MNG) with hypothyroidism, covering pathophysiology, clinical presentation, diagnosis, and management.

search_medical_text

multinodular goiter hypothyroidism pathophysiology diagnosis management

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 10749

search_medical_text

thyroid nodule evaluation TSH levothyroxine treatment guidelines

Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Page 11

search_medical_image

multinodular goiter thyroid ultrasound imaging

Hugging Face pmc clinical VQA raw

Page 0

GradeResponse

Here is a comprehensive overview of multinodular goiter (MNG) with hypothyroidism:

Multinodular Goiter with Hypothyroidism

Overview

A multinodular goiter (MNG) is an enlarged thyroid gland containing multiple nodules of varying size and composition. While MNG is more classically associated with euthyroidism or hyperthyroidism (toxic MNG), it can coexist with hypothyroidism — typically due to underlying autoimmune thyroiditis (Hashimoto's) destroying functional thyroid tissue despite structural enlargement, or iodine deficiency.

Pathophysiology

Mechanism	Details
Iodine deficiency	Chronic low iodine → elevated TSH → diffuse goiter → nodule formation over years
Hashimoto's thyroiditis	Autoimmune destruction of follicles → compensatory TSH rise → nodularity + eventual hypothyroidism
Dyshormonogenesis	Genetic enzyme defects (e.g., thyroid peroxidase mutations) → impaired T4/T3 synthesis → chronic TSH stimulation → MNG
DICER1 mutations	Germline mutations predispose to MNG and associated malignancies
Sporadic/multifactorial	Somatic mutations in nodules (TSH-R, Gs-α) with background hypothyroidism

The core pathway: chronic TSH stimulation → hyperplastic nodule growth → heterogeneous autonomy and cystic degeneration.

Clinical Presentation

Symptoms of MNG (structural):

Visible or palpable neck mass, often asymmetric
Dysphagia (esophageal compression)
Dyspnea or stridor (tracheal compression)
Hoarseness (recurrent laryngeal nerve involvement — raises concern for malignancy)
Superior vena cava syndrome (large substernal goiters)

Symptoms of hypothyroidism:

Fatigue, cold intolerance, weight gain
Constipation, dry skin, coarse hair, brittle nails
Bradycardia, diastolic hypertension
Myxedema (periorbital/peripheral puffiness)
Cognitive slowing, depression
Menstrual irregularities

Diagnosis

Lab Evaluation

Test	Finding in MNG + Hypothyroidism
TSH	Elevated (primary hypothyroidism)
Free T4	Low (overt) or normal (subclinical)
Free T3	Low or normal
Anti-TPO antibodies	Positive → suggests Hashimoto's etiology
Anti-thyroglobulin Ab	May be positive

Per ATA guidelines, serum TSH should be obtained for any thyroid nodule >1 cm. A higher TSH — even within the upper normal range — is associated with increased malignancy risk in thyroid nodules (ATA Thyroid Nodule & DTC Guidelines, p. 11).

Imaging

Thyroid ultrasound is the primary imaging modality:

Multinodular goiter on transverse grayscale ultrasound showing multiple nodules of varying echogenicity, cystic degeneration, and architectural distortion

Transverse grayscale ultrasound of multinodular goiter: multiple nodules of heterogeneous echotexture (hypoechoic, isoechoic, hyperechoic), cystic degeneration, and distorted gland architecture.

Ultrasound features to assess:

Number, size, composition (solid vs. cystic)
Echogenicity and margins
Microcalcifications (suspicious for malignancy)
Vascularity (Doppler)
Lymphadenopathy

Radionuclide scan (¹²³I or Tc-99m):

Indicated if TSH is subnormal (to identify hot/warm/cold nodules)
In hypothyroid MNG, TSH is elevated → scan less useful to differentiate autonomy; ultrasound preferred
Cold nodules have higher malignancy risk; hot nodules rarely malignant

Fine Needle Aspiration (FNA)

Indicated for nodules with suspicious sonographic features (TIRADS 4–5) or size thresholds per ATA/ACR guidelines
In MNG, the dominant or most suspicious nodule guides FNA decisions
Bethesda system classifies cytology (I–VI)

Management

1. Treat the Hypothyroidism

Levothyroxine (LT4) is the standard of care for overt hypothyroidism
- Dose: ~1.6 mcg/kg/day (adjusted by TSH)
- Target TSH: 0.5–2.5 mIU/L (lower end reasonable in younger patients)
- Subclinical hypothyroidism (TSH 4–10): treat if symptomatic, anti-TPO positive, pregnant, or TSH >10

2. Goiter/Nodule Management

Per Harrison's 21st Edition (p. 10749):

"Most nontoxic MNGs can be managed conservatively. T₄ suppression is rarely effective for reducing goiter size and introduces the risk of subclinical or overt thyrotoxicosis, particularly if there is underlying autonomy."

Option	Indication	Notes
LT4 alone	Hypothyroid MNG with Hashimoto's	Treats hypothyroidism; not given to suppress TSH below normal
Radioiodine (¹³¹I)	Large MNG unsuitable for surgery	Reduces volume 40–60%; dose ~3.7 MBq/g tissue corrected for uptake; repeat may be needed (Harrison's, p. 10749)
Surgery (thyroidectomy)	Compressive symptoms, suspicious malignancy, large substernal goiter, cosmesis	Total or near-total thyroidectomy; post-op LT4 replacement mandatory
Watchful waiting	Small asymptomatic MNG, benign cytology, stable TSH management	Serial ultrasound q12–24 months
Percutaneous ethanol injection / RFA	Select benign cystic/solid nodules	Emerging; reduces nodule volume

Note: Avoid iodine-containing contrast agents (risk of Jod-Basedow thyrotoxicosis if autonomous nodules are present), though this is less relevant in purely hypothyroid patients.

Special Considerations

Substernal/retrosternal MNG: May cause SVC syndrome, Pemberton's sign (facial congestion on arm elevation); CT chest for airway assessment; surgical referral often needed
Malignancy surveillance: MNG does not significantly increase overall cancer risk, but each dominant/suspicious nodule must be evaluated independently
Pregnancy: TSH targets are trimester-specific; LT4 dose often needs to increase 25–30% in first trimester
Elderly: Subclinical hypothyroidism may be left untreated cautiously; risk of atrial fibrillation with over-replacement

Summary Algorithm

MNG detected
    ↓
Check TSH
    ↓
TSH Elevated (Hypothyroidism)
    ↓
Free T4, anti-TPO, anti-TG antibodies
    ↓
Thyroid ultrasound → characterize nodules (TIRADS)
    ↓
FNA of suspicious/dominant nodules (per ATA criteria)
    ↓
Start LT4 for hypothyroidism
    ↓
Compressive symptoms / large goiter / malignancy concern?
    → Yes: Surgery or ¹³¹I (if surgery contraindicated)
    → No: Serial surveillance ultrasound q12–24 months

Sources:

Harrison's Principles of Internal Medicine, 21st Edition, p. 10749
ATA Guidelines: Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer, p. 11

This is a shared conversation. Sign in to Orris to start your own chat.